CIK 0001563880 · Non-accelerated filer<br>Smaller reporting company
Trevi Therapeutics, Inc.
Sign in to watch- Ticker
- TRVI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450834299
- Phone
- 203-304-2499
- Business address
- 195 CHURCH STREET, 16TH FLOOR, NEW HAVEN, CT, 06510
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $595,806
- in 1 filing, $596K under 10b5-1 plans
Net −$595,806. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-05-11 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,291 | $0.51 | $1K | 28,480 |
| 2023-05-11 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −562 | $2.89 | $2K | 27,918 |
| 2023-05-11 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,291 | 75,626 | ||
| 2023-04-11 | Delfini Lisa Chief Financial Officer | Option exercise 10b5-1 | +2,292 | $0.51 | $1K | 27,029 |
| 2023-04-11 | Delfini Lisa Chief Financial Officer | Sale 10b5-1 | −840 | $1.84 | $2K | 26,189 |
| 2023-04-11 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −2,292 | 77,917 | ||
| 2023-03-13 | Delfini Lisa Chief Financial Officer | Option exercise | +2,291 | $0.51 | $1K | 25,629 |
| 2023-03-13 | Delfini Lisa Chief Financial Officer | Sale | −892 | $1.75 | $2K | 24,737 |
| 2023-03-13 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) | −2,291 | 80,209 | ||
| 2023-03-07 | Simon Farrell Chief Commercial Officer | Option exercise | +18,750 | $0.51 | $10K | 39,400 |
| 2023-03-07 | Simon Farrell Chief Commercial Officer | Option exercise · Stock Option (right to buy) | −18,750 | 56,250 | ||
| 2023-02-16 | Galletta Christopher See Remarks | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2023-02-16 | Simon Farrell Chief Commercial Officer | Grant or award · Stock Option (right to buy) | +100,000 | 100,000 | ||
| 2023-02-16 | SCIASCIA THOMAS Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +187,500 | 187,500 | ||
| 2023-02-16 | Delfini Lisa Chief Financial Officer | Grant or award · Stock Option (right to buy) | +187,500 | 187,500 | ||
| 2023-02-16 | GOOD JENNIFER L President & CEO | Grant or award · Stock Option (right to buy) | +375,000 | 375,000 | ||
| 2023-02-13 | Delfini Lisa Chief Financial Officer | Option exercise | +27,500 | $0.51 | $14K | 31,812 |
| 2023-02-13 | Delfini Lisa Chief Financial Officer | Sale | −8,474 | $2.45 | $21K | 23,338 |
| 2023-02-13 | Delfini Lisa Chief Financial Officer | Option exercise · Stock Option (right to buy) | −27,500 | 82,500 | ||
| 2022-11-14 | Clark David J Chief Medical Officer | Grant or award · Stock Option (right to buy) | +300,000 | 300,000 |
Page 8 of 9 · 179 trades